What is the difference between autologous and allogeneic bone marrow transplant?
An autologous bone marrow transplant uses the patient's own stem cells, while an allogeneic bone marrow transplant uses stem cells from a matched donor. The choice depends on the underlying condition, disease stage, and availability of a compatible donor. SL Raheja Hospital in Mumbai offers bone marrow transplant (BMT) evaluation and treatment to help patients and families understand which approach is appropriate.
Tip: Both transplant types involve high-dose chemotherapy or radiation to destroy diseased marrow before infusing healthy stem cells. The source of those cells is the defining difference.
What are the key differences between autologous and allogeneic bone marrow transplants?
The table below summarises the principal clinical distinctions between the two transplant types, including a third category — syngeneic — which applies when the donor is an identical twin.
| Feature | Autologous | Allogeneic | Syngeneic |
|---|---|---|---|
| Stem cell source | Patient's own cells | Matched donor | Identical twin |
| Donor matching required | No | Yes (HLA typing) | No (genetically identical) |
| Graft-versus-host disease (GvHD) risk | None | Significant risk | Minimal |
| Graft-versus-tumour effect | Absent | Present (beneficial) | Minimal |
| Risk of relapse from contaminated cells | Higher | Lower | Moderate |
| Typical recovery complexity | Generally lower | Generally higher | Moderate |
Understanding bone marrow transplant options at SL Raheja Hospital begins with a thorough haematology assessment to determine which transplant type is clinically appropriate.
What are the three types of bone marrow transplants and which conditions require each?
Bone marrow transplants are broadly classified into three types based on the source of stem cells. The clinical indication largely determines which type is used.
- Autologous BMT — Stem cells are harvested from the patient before high-dose chemotherapy, then reinfused. Commonly used for multiple myeloma, non-Hodgkin lymphoma, and Hodgkin lymphoma where the bone marrow itself is not diseased.
- Allogeneic BMT — Stem cells come from a matched related or unrelated donor. Used for acute leukaemia, chronic leukaemia, aplastic anaemia, myelodysplastic syndromes, and certain inherited blood disorders such as thalassaemia and sickle cell disease.
- Syngeneic BMT — Stem cells come from an identical twin. Rare, but eliminates GvHD risk while providing healthy donor cells.
Conditions such as leukaemia and aplastic anaemia often require allogeneic transplantation because the patient's own marrow is the source of disease. Patients with blood disorders managed through haematology at SL Raheja Hospital are assessed individually before a transplant type is recommended.
What are the disadvantages and risks of each transplant type?
Both transplant types carry significant risks. Understanding them helps patients make informed decisions alongside their clinical team.
Autologous BMT — key disadvantages:
- No graft-versus-tumour effect, so residual cancer cells are not attacked by donor immunity.
- Harvested stem cells may contain cancer cells, increasing relapse risk.
- Not suitable when the bone marrow itself is diseased or heavily infiltrated.
- Disease relapse rates can be higher compared to allogeneic transplant for certain cancers.
Allogeneic BMT — key disadvantages:
- Graft-versus-host disease (GvHD) — donor immune cells attack the recipient's tissues. Can be acute or chronic and ranges from mild to life-threatening.
- Requires a compatible donor (HLA-matched), which is not always available.
- Higher risk of serious infection due to prolonged immune suppression.
- Longer and more complex recovery period.
- Risk of graft failure (donor cells do not engraft successfully).
Warning: Graft-versus-host disease is a serious complication of allogeneic transplant. Symptoms include skin rash, persistent diarrhoea, and abnormal liver function. Report any such symptoms to your transplant team immediately.
Who is eligible for autologous or allogeneic stem cell transplant?
Eligibility for either transplant type depends on several clinical and logistical factors. A specialist BMT team evaluates each patient individually.
Autologous transplant eligibility — typical criteria:
- Diagnosis of a condition where the patient's own marrow is not the primary disease source (e.g. multiple myeloma, lymphoma).
- Adequate organ function (heart, lungs, kidneys, liver).
- Sufficient stem cell harvest possible from the patient.
- Disease that is chemotherapy-sensitive.
- Generally, patients up to a certain age and performance status as assessed by the treating team.
Allogeneic transplant eligibility — typical criteria:
- Conditions where the patient's own marrow is diseased (leukaemia, aplastic anaemia, thalassaemia).
- Availability of an HLA-matched related donor (sibling, parent) or matched unrelated donor.
- Adequate organ function to tolerate the conditioning regimen and immunosuppression.
- Disease status that makes transplant risk acceptable relative to benefit.
Patients with conditions such as leukaemia may also benefit from a review of medical oncology services at SL Raheja Hospital as part of their overall treatment planning.
How is a donor matched for allogeneic bone marrow transplant?
Donor matching for allogeneic BMT relies on Human Leukocyte Antigen (HLA) typing, a blood test that analyses proteins on the surface of white blood cells. A close HLA match reduces the risk of GvHD and graft failure.
- Related donor search — Siblings have a 25% chance of being a full HLA match. Parents and children are partial matches (haploidentical).
- Unrelated donor search — If no matched sibling is available, national and international bone marrow registries are searched for a matched unrelated donor (MUD).
- Haploidentical transplant — A half-matched family member (parent, child, or sibling) can sometimes be used with special protocols to reduce GvHD risk.
- Cord blood transplant — Umbilical cord blood units from registries can serve as an alternative source when a matched adult donor is unavailable.
Tip: A sibling is the first donor considered for allogeneic BMT. If no matched sibling exists, the transplant team will initiate a registry search. This process can take weeks, so early referral is important.
When should you consult a BMT specialist at SL Raheja Hospital?
Seek a bone marrow transplant consultation promptly if any of the following apply. Early referral allows time for donor searches, pre-transplant workup, and treatment planning.
- A haematologist or oncologist has recommended BMT as part of your treatment plan.
- You have been diagnosed with acute leukaemia, chronic leukaemia, aplastic anaemia, myelodysplastic syndrome, multiple myeloma, or lymphoma.
- You or a family member has an inherited blood disorder such as thalassaemia or sickle cell disease that has not responded adequately to other treatments.
- You have relapsed after initial chemotherapy and transplant is being considered as salvage therapy.
- You want a second opinion on whether autologous or allogeneic transplant is more appropriate for your diagnosis.
SL Raheja Hospital in Mumbai, located at Raheja Rugnalaya Marg, Mahim West, provides specialist BMT consultations. Use the booking form on this page to schedule an appointment, or contact the hospital directly at info@rahejahospital.com.
Patients with related metabolic or endocrine conditions affecting treatment eligibility may also benefit from a review through endocrinology services at SL Raheja Hospital.
Book a BMT consultation at SL Raheja Hospital, Mumbai
Use the booking form on this page, or email us at info@rahejahospital.com